EA202091615A1 - Интраназальные составы на основе эпинефрина и способы лечения заболевания - Google Patents
Интраназальные составы на основе эпинефрина и способы лечения заболеванияInfo
- Publication number
- EA202091615A1 EA202091615A1 EA202091615A EA202091615A EA202091615A1 EA 202091615 A1 EA202091615 A1 EA 202091615A1 EA 202091615 A EA202091615 A EA 202091615A EA 202091615 A EA202091615 A EA 202091615A EA 202091615 A1 EA202091615 A1 EA 202091615A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- epinephrine
- methods
- treating
- disease
- formulations based
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Представлены лекарственные препараты, выполненные с возможностью назальной доставки, содержащие составы с эпинефрином, и устройства, содержащие такие составы. Также представлены способы лечения анафилаксии с помощью продуктов на основе эпинефрина.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862784057P | 2018-12-21 | 2018-12-21 | |
PCT/US2019/016918 WO2019157099A1 (en) | 2018-02-06 | 2019-02-06 | Intranasal epinephrine formulations and methods for the treatment of disease |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202091615A1 true EA202091615A1 (ru) | 2021-03-05 |
Family
ID=67548575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202091615A EA202091615A1 (ru) | 2018-12-21 | 2019-02-06 | Интраназальные составы на основе эпинефрина и способы лечения заболевания |
Country Status (4)
Country | Link |
---|---|
US (8) | US20190269782A1 (ru) |
JP (2) | JP6941224B2 (ru) |
EA (1) | EA202091615A1 (ru) |
WO (1) | WO2019157099A1 (ru) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
WO2019182745A1 (en) | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
EA202091615A1 (ru) | 2018-12-21 | 2021-03-05 | Аегис Терапьютикс, Ллс | Интраназальные составы на основе эпинефрина и способы лечения заболевания |
US11433063B1 (en) | 2019-03-12 | 2022-09-06 | Belhaven Biopharma, Inc. | Intranasal composition of pharmaceutical countermeasures for chemical warfare nerve agents and accidental exposure to organophosphate pesticides |
JP7499026B2 (ja) | 2019-12-27 | 2024-06-13 | 小林製薬株式会社 | 内服用医薬組成物 |
WO2021158957A1 (en) * | 2020-02-05 | 2021-08-12 | Summit Biosciences Inc. | Drug products for intranasal administration and uses thereof |
US20210283074A1 (en) * | 2020-03-16 | 2021-09-16 | Nasus Pharma Ltd. | Polymeric Compositions for Intranasal Administration |
IL297758A (en) * | 2020-04-30 | 2022-12-01 | Purdue Pharma Lp | The vehicles and methods for emergency rescue |
EP4146246A4 (en) * | 2020-05-04 | 2024-05-29 | Amphastar Pharmaceuticals, Inc. | SAFE USE OF BILE ACIDS AND THEIR SALTS AS ACTIVATORS FOR NASAL DELIVERY OF PHARMACEUTICALS |
US20230181500A1 (en) * | 2020-05-04 | 2023-06-15 | Amphastar Pharmaceuticals, Inc. | Naloxone Pharmaceutical Formulations for Intranasal (IN) Delivery |
SI3962455T1 (sl) | 2020-05-18 | 2022-11-30 | Orexo Ab | Nov farmacevtski sestavek za dostavo zdravil |
US11439651B2 (en) * | 2020-10-18 | 2022-09-13 | CoFix-RX, LLC | Nasal spray composition for COVID-19 and SARS and method of forming the same |
WO2022129069A1 (en) * | 2020-12-17 | 2022-06-23 | Philip Morris Products S.A. | Pharmaceutical composition comprising epinephrine for aerosol administration |
US11617716B2 (en) * | 2021-06-10 | 2023-04-04 | Belhaven BioPharma Inc. | Dry powder formulations of epinephrine and associated methods |
EP4236921A1 (en) | 2021-11-25 | 2023-09-06 | Orexo AB | Pharmaceutical composition comprising adrenaline |
US12005185B2 (en) | 2021-12-17 | 2024-06-11 | Belhaven BioPharma Inc. | Medical counter measures including dry powder formulations and associated methods |
WO2024082281A1 (en) * | 2022-10-21 | 2024-04-25 | Nanjing Haiwei Pharmaceutical Technologies Co., Ltd. | Novel formulations of epinephrine and uses thereof |
WO2024110426A1 (en) | 2022-11-23 | 2024-05-30 | F. Hoffmann-La Roche Ag | Method for increasing recombinant protein expression |
CN117982521B (zh) * | 2024-04-03 | 2024-06-25 | 首都医科大学附属北京同仁医院 | 一种治疗鼻病的组合物、制剂及其制备方法 |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1003971A (en) | 1908-11-14 | 1911-09-26 | United Shoe Machinery Ab | Sole-pressing machine. |
US1026540A (en) | 1911-05-31 | 1912-05-14 | C E Cole | Washing-machine. |
US3547828A (en) | 1968-09-03 | 1970-12-15 | Rohm & Haas | Alkyl oligosaccharides and their mixtures with alkyl glucosides and alkanols |
DK149776C (da) | 1984-01-06 | 1987-04-21 | Orion Yhtymae Oy | Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen |
US5192528A (en) | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
JPH01151528A (ja) | 1987-12-08 | 1989-06-14 | Taiho Yakuhin Kogyo Kk | 経粘膜吸収促進剤 |
US5369095A (en) | 1990-02-14 | 1994-11-29 | Alcon Laboratories, Inc. | Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers |
US5252318A (en) | 1990-06-15 | 1993-10-12 | Allergan, Inc. | Reversible gelation compositions and methods of use |
ES2095348T3 (es) | 1991-05-16 | 1997-02-16 | Kao Corp | Solucion acuosa de alquilglucosido estable contra la actividad microbiana. |
WO1994005262A1 (en) | 1992-09-10 | 1994-03-17 | F.H. Faulding & Co. Limited | Sustained release matrix composition |
US5661130A (en) | 1993-06-24 | 1997-08-26 | The Uab Research Foundation | Absorption enhancers for drug administration |
CA2174324A1 (en) | 1993-10-21 | 1995-04-27 | Katsuya Mukae | Pernasal composition and pernasal preparation containing the same |
SE9404196D0 (sv) | 1994-12-02 | 1994-12-02 | Astra Ab | New antithrombotic formulation |
EE9700138A (et) | 1994-12-22 | 1997-12-15 | Astra Aktiebolag | Aerosoolravimvormid |
SE9404468D0 (sv) | 1994-12-22 | 1994-12-22 | Astra Ab | Powder formulations |
US6524557B1 (en) | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
TWI223598B (en) | 1998-06-22 | 2004-11-11 | Pfizer Ireland Pharmaceuticals | An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate |
US6608073B1 (en) | 1998-10-14 | 2003-08-19 | New Millennium Pharmaceutical Research, Inc. | Intranasal codeine for the rapid suppression of cough and rapid relief of pain |
EP1183027A4 (en) | 1999-06-16 | 2003-02-05 | Nastech Pharmaceutical Co | PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRA-NASAL DELIVERY MORPHINE |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
IL150109A0 (en) | 1999-12-09 | 2002-12-01 | Chiron Corp | Method for administering a cytokine to the central nervous system and the lymphatic system |
US6610271B2 (en) | 2000-05-10 | 2003-08-26 | University Of Kentucky Research Foundation | System and method for intranasal administration of lorazepam |
US6551578B2 (en) | 2001-02-15 | 2003-04-22 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
US6855332B2 (en) | 2002-07-03 | 2005-02-15 | Lyfjathroun Hf. | Absorption promoting agent |
WO2004093917A2 (en) | 2003-04-22 | 2004-11-04 | Nastech Pharmaceutical Company Inc. | Intranasal administration of triptans |
GB0310919D0 (en) | 2003-05-13 | 2003-06-18 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
JP2007502839A (ja) | 2003-08-21 | 2007-02-15 | トランソラル ファーマシューティカルズ,インコーポレイティド | 口腔粘膜を介して5−htアゴニストを運搬するための組成物及びその使用方法 |
DE102004017934A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
US20090047347A1 (en) | 2005-07-29 | 2009-02-19 | Aegis Therapeutics, Inc. | Compositions for Drug Administration |
US8268791B2 (en) | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
EP2457580A1 (en) | 2004-08-25 | 2012-05-30 | The UAB Research Foundation | Absorption enhancers for drug administration |
US20120021980A1 (en) | 2004-08-25 | 2012-01-26 | Aegis Therapeutics, Inc. | Compositions for drug administration |
US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
US20140162965A1 (en) | 2004-08-25 | 2014-06-12 | Aegis Therapeutics, Inc. | Compositions for oral drug administration |
US9114069B2 (en) | 2004-08-25 | 2015-08-25 | Aegis Therapeutics, Llc | Antibacterial compositions for drug administration |
US8642564B2 (en) | 2004-08-25 | 2014-02-04 | Aegis Therapeutics, Llc | Compositions for drug administration |
US20060046969A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Antibacterial compositions for drug administration |
TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
US20070293582A1 (en) | 2006-06-05 | 2007-12-20 | Malcolm Hill | Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms |
US8084022B2 (en) | 2006-06-23 | 2011-12-27 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
US7998927B2 (en) | 2006-06-23 | 2011-08-16 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
US7425542B2 (en) | 2006-06-23 | 2008-09-16 | Aegis Therapeutics, Inc. | Stabilizing alkylglycoside compositions and methods thereof |
US20090326193A1 (en) | 2006-06-23 | 2009-12-31 | Aegis Therapeutics Llc | Stabilizing alkylglycoside compositions and methods thereof |
HUE048024T2 (hu) * | 2006-08-10 | 2020-05-28 | Roy C Levitt | Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra |
US20090004281A1 (en) | 2007-06-26 | 2009-01-01 | Biovail Laboratories International S.R.L. | Multiparticulate osmotic delivery system |
US20090258865A1 (en) | 2008-03-28 | 2009-10-15 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine compositions |
US8715715B2 (en) | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
US8440631B2 (en) | 2008-12-22 | 2013-05-14 | Aegis Therapeutics, Llc | Compositions for drug administration |
US20100203014A1 (en) | 2009-02-04 | 2010-08-12 | Aegis Therapeutics Llc | Zwitterionic buffered acidic peptide and protein formulations |
ES2553862T3 (es) | 2009-09-25 | 2015-12-14 | Dr. Reddy's Laboratories Ltd. | Formulaciones que comprenden compuestos de triptán |
WO2011139838A2 (en) | 2010-04-28 | 2011-11-10 | Zelos Therapeutics, Inc. | Intranasal formulations |
EP2747563A4 (en) | 2011-08-26 | 2015-06-24 | Aegis Therapeutics Llc | COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS |
US9789071B2 (en) | 2012-06-27 | 2017-10-17 | G2B Pharma, Inc. | Intranasal formulation of epinephrine for the treatment of anaphylaxis |
US20150374832A1 (en) | 2013-02-12 | 2015-12-31 | Ys Pharm Tech | Epinephrine formulations for medicinal products |
AU2014315459A1 (en) | 2013-09-03 | 2016-04-07 | G2B Pharma Inc. | Intranasal formulation for the treatment of cardiopulmonary resuscitation (CPR), cardiac life support (CLS), anaphylaxis and/or anaphylactoid reactions |
EP3082817A4 (en) | 2013-12-18 | 2017-06-21 | Aegis Therapeutics, LLC | Compositions for drug administration |
US9561177B2 (en) | 2014-03-14 | 2017-02-07 | Adapt Pharma Limited | Nasal drug products and methods of their use |
US9480644B2 (en) | 2014-03-14 | 2016-11-01 | Opiant Pharmaceuticals, Inc. | Nasal drug products and methods of their use |
US20160051494A1 (en) | 2014-08-21 | 2016-02-25 | Mylan, Inc. | Multi-dose medication kit for treating anaphylaxis |
US10039710B2 (en) | 2015-09-18 | 2018-08-07 | Insys Development Company, Inc. | Epinephrine spray formulations |
US20170079907A1 (en) | 2015-09-18 | 2017-03-23 | Insys Development Company, Inc. | Sublingual Epinephrine Spray |
US11517525B2 (en) | 2015-09-18 | 2022-12-06 | Hikma Pharmaceuticals Usa Inc. | Epinephrine spray formulations |
US11571384B2 (en) | 2015-09-18 | 2023-02-07 | Hikma Pharmaceuticals Usa Inc. | Epinephrine spray formulations |
AU2017360910B2 (en) | 2016-11-18 | 2023-11-23 | Aegis Therapeutics, Llc | Compositions and methods for the treatment of opioid overdose |
WO2018195029A1 (en) | 2017-04-17 | 2018-10-25 | Insys Development Company, Inc. | Epinephrine spray formulations |
EA202091615A1 (ru) | 2018-12-21 | 2021-03-05 | Аегис Терапьютикс, Ллс | Интраназальные составы на основе эпинефрина и способы лечения заболевания |
-
2019
- 2019-02-06 EA EA202091615A patent/EA202091615A1/ru unknown
- 2019-02-06 WO PCT/US2019/016918 patent/WO2019157099A1/en unknown
- 2019-02-06 JP JP2020505498A patent/JP6941224B2/ja active Active
- 2019-05-22 US US16/420,051 patent/US20190269782A1/en not_active Abandoned
- 2019-05-22 US US16/420,044 patent/US10682414B2/en active Active
- 2019-05-22 US US16/420,034 patent/US20190269780A1/en not_active Abandoned
-
2020
- 2020-05-07 US US16/869,461 patent/US11191838B2/en active Active
-
2021
- 2021-08-06 US US17/396,044 patent/US11744895B2/en active Active
- 2021-08-20 JP JP2021135018A patent/JP2021193091A/ja active Pending
-
2022
- 2022-10-26 US US18/049,936 patent/US11717571B2/en active Active
-
2023
- 2023-06-01 US US18/327,621 patent/US20230302137A1/en active Pending
- 2023-06-07 US US18/206,881 patent/US11918655B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US11918655B2 (en) | 2024-03-05 |
US20190269780A1 (en) | 2019-09-05 |
US11744895B2 (en) | 2023-09-05 |
JP2021193091A (ja) | 2021-12-23 |
JP2021508670A (ja) | 2021-03-11 |
US11191838B2 (en) | 2021-12-07 |
US20240024485A1 (en) | 2024-01-25 |
US20190269782A1 (en) | 2019-09-05 |
US20230085636A1 (en) | 2023-03-23 |
JP6941224B2 (ja) | 2021-09-29 |
US11717571B2 (en) | 2023-08-08 |
US10682414B2 (en) | 2020-06-16 |
US20230302137A1 (en) | 2023-09-28 |
US20210361770A1 (en) | 2021-11-25 |
US20190269781A1 (en) | 2019-09-05 |
WO2019157099A1 (en) | 2019-08-15 |
US20200261582A1 (en) | 2020-08-20 |
WO2019157099A8 (en) | 2019-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202091615A1 (ru) | Интраназальные составы на основе эпинефрина и способы лечения заболевания | |
PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
EA202091964A1 (ru) | КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
MX2019000588A (es) | Moduladores de la somatostatina y usos de los mismos. | |
SA516380290B1 (ar) | نواقل لفيروس مرتبط بالغدد لعلاج اضطرابات الاختزان في الجسيمات الحالة | |
MX2019010949A (es) | Moduladores de somatostatina y usos de los mismos. | |
EA201892327A1 (ru) | Ингаляционные и назальные бензодиазепины | |
CY1122716T1 (el) | Ρινικη συσταση κονεως για την αγωγη της υπογλυκαιμιας | |
AU2018348359A8 (en) | Extended release pharmaceutical formulation and methods of treatment | |
BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
WO2018115432A3 (en) | COMPOUNDS FOR THE TREATMENT OF BOVINE OR PORCINE RESPIRATORY DISEASE | |
EA202191067A1 (ru) | Композиции и способы для лечения дефицита альфа-1-антитрипсина | |
MX2020007586A (es) | Proceso de fabricacion de moduladores de somatostatina. | |
EA201892265A1 (ru) | Способы лечения офтальмологических заболеваний | |
EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
EA202091095A1 (ru) | Пероральная доставка пептидных аналогов glp-1 | |
CO2018000171A2 (es) | Metodos de purificacion y/o inactividad viral | |
CY1125031T1 (el) | Μεθοδος για γενετικη θεραπεια χρησιμοποιωντας τον ιο aav-xbp1s/gfp και χρηση αυτης στην προληψη και τη θεραπεια της αμυοτροφικης πλευρικης σκληρυνσης | |
UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
MX2018002298A (es) | Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos. | |
EA201792312A1 (ru) | Конструкции на основе калихеамицина и способы их применения | |
MX2017009164A (es) | Moduladores de canales de ca2+ activados de liberacion de ca2+ (crac) y usos farmaceuticos de los mismos. | |
BR112021014566A2 (pt) | Moduladores de gpr35 | |
MX2023002506A (es) | Formulaciones de epinefrina intranasal y metodos para el tratamiento de enfermedades. | |
MX2018005226A (es) | Formulaciones de anticuerpo anti-factor d. |